2023 World Conference on Lung Cancer (Posters)-EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort

EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort - PDF(Abstract)

Back to course

Pdf Summary

This study focused on long-term survivors with EGFR positive non-small cell lung cancer (NSCLC) who were treated with tyrosine kinase inhibitors (TKIs). The researchers aimed to identify the clinical characteristics associated with long-term survival in these patients.<br /><br />The study included patients with de novo advanced EGFRmut NSCLC who received a 1st/2nd generation EGFR-TKI between 2004 and 2016. Data on demographic, clinical, treatment, and outcome details were collected from the Alberta Glans-Look Lung Cancer Research Database (GLR) and Ontario's Princess Margaret Cancer Centre (PM).<br /><br />The results showed that out of 358 patients, the median overall survival was 23.2 months. The long-term survivors (LTS) had a median survival of 56 months from TKI initiation, while the remaining patients were described as 'average term survivors' (ATS) with a median survival of 17.5 months.<br /><br />Although there were no significant differences in most clinical and pathological characteristics between the LTS and ATS cohorts, the LTS patients were more likely to be Asians compared to non-Asians. It was also found that PM patients were more likely to be Asian and had longer median survival outcomes compared to GLR patients.<br /><br />In the multivariate analysis, both PM and Asian ethnicity were identified as independent prognostic factors for longer survival times. On the other hand, males and the L858R mutation were prognosticators of shorter overall survival.<br /><br />The study confirmed previous findings that Asian ancestry, males, and the L858R mutation are prognostic factors in EGFR positive NSCLC. The researchers emphasized the need for further research to understand the biological reasons for ethnic differences in prognosis and the impact of socioeconomic factors on management.<br /><br />In summary, this multicentre study identified clinical characteristics associated with long-term survival in patients with EGFR positive NSCLC treated with TKIs. Asian ethnicity, the presence of the L858R mutation, and being treated at the Princess Margaret Cancer Centre were associated with better survival outcomes.

Asset Subtitle

Heather Halperin

Meta Tag

Speaker Heather Halperin

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

long-term survivors

EGFR positive non-small cell lung cancer

tyrosine kinase inhibitors

clinical characteristics

survival

de novo advanced EGFRmut NSCLC

1st/2nd generation EGFR-TKI

Alberta Glans-Look Lung Cancer Research Database

Princess Margaret Cancer Centre

overall survival